Left ventricular hypertrophy: Unresolved issues

[1] Ghali J.K., Liao Y., Summons B., Et al., The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease, Ann Intern Med, 117, pp. 831-836, (1992)

[2] Levy D., Anderson K.M., Savage D.D., Et al., Echocardiographically detected left ventricular hypertrophy: Prevalenc and risk factors. The Framingham Heart Study, Ann Intern Med, 108, pp. 7-13, (1988)

[3] Gottdiener J.S., Reds D.J., Materson B.J., Et al., Importance of obesity, race, and age to the cardiac structural and functional effects of hypertension, J Am Coll Cardiol, 24, pp. 1492-1498, (1994)

[4] Liebson P.R., Clinical studies of drug reversal of hypertensive left ventricular hypertrophy, Am J Hypertens, 3, pp. 512-517, (1990)

[5] Tremarco B., Wikstrand J., Regression of cardiovascular structural changes by anti-hypertensive treatment: Functional consequences and time course of reversal as judged from clinical studies, Hypertension, 6, SUPPL. 3, pp. 111-150, (1984)

[6] Gottdiener J.S., Clinical trials of single-drug therapy for the cardiac effects of hypertension, American Journal of Hypertension, 12, PART 2, (1999)

[7] Dahlof B., Pennert K., Hansson L., Reversal of left ventricular hypertrophy in hypertensive patients: A meta-analyses of 109 treatment studies, Am J Hypertens, 5, pp. 95-110, (1992)

[8] Schmieder R.E., Martus P., Klingbeil A., Reversal of left ventricular hypertrophy in essential hypertension: A metaanalysis of randomized double-blind studies, JAMA, 275, pp. 1507-1513, (1996)

[9] Liebson P.R., Grandets G.A., Dianzumba S., Et al., Comparison of five antihypertensive mono-therapies and placebo for change in left ventricular mass in patients receiving mutulionalhygienic therapy in the Treatment of Mild Hypertension Study (TOMHS), Circulation, 91, pp. 698-706, (1995)

[10] Materson B.J., Rede D.J., Cushman W.C., Et al., Single-drug therapy for hypertension in men: Comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on antihypertensive agents, N Engl J Med, 328, pp. 914-921, (1993)

[1] Ghali J.K., Liao Y., Summons B., Et al., The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease, Ann Intern Med, 117, pp. 831-836, (1992)

[2] Levy D., Anderson K.M., Savage D.D., Et al., Echocardiographically detected left ventricular hypertrophy: Prevalenc and risk factors. The Framingham Heart Study, Ann Intern Med, 108, pp. 7-13, (1988)

[3] Gottdiener J.S., Reds D.J., Materson B.J., Et al., Importance of obesity, race, and age to the cardiac structural and functional effects of hypertension, J Am Coll Cardiol, 24, pp. 1492-1498, (1994)

[4] Liebson P.R., Clinical studies of drug reversal of hypertensive left ventricular hypertrophy, Am J Hypertens, 3, pp. 512-517, (1990)

[5] Tremarco B., Wikstrand J., Regression of cardiovascular structural changes by anti-hypertensive treatment: Functional consequences and time course of reversal as judged from clinical studies, Hypertension, 6, SUPPL. 3, pp. 111-150, (1984)

[6] Gottdiener J.S., Clinical trials of single-drug therapy for the cardiac effects of hypertension, American Journal of Hypertension, 12, PART 2, (1999)

[7] Dahlof B., Pennert K., Hansson L., Reversal of left ventricular hypertrophy in hypertensive patients: A meta-analyses of 109 treatment studies, Am J Hypertens, 5, pp. 95-110, (1992)

[8] Schmieder R.E., Martus P., Klingbeil A., Reversal of left ventricular hypertrophy in essential hypertension: A metaanalysis of randomized double-blind studies, JAMA, 275, pp. 1507-1513, (1996)

[9] Liebson P.R., Grandets G.A., Dianzumba S., Et al., Comparison of five antihypertensive mono-therapies and placebo for change in left ventricular mass in patients receiving mutulionalhygienic therapy in the Treatment of Mild Hypertension Study (TOMHS), Circulation, 91, pp. 698-706, (1995)

[10] Materson B.J., Rede D.J., Cushman W.C., Et al., Single-drug therapy for hypertension in men: Comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on antihypertensive agents, N Engl J Med, 328, pp. 914-921, (1993)